SK Biopharm Signs Pharmaceutical Supply Contract Worth 66.4 Billion KRW

[Asia Economy Reporter Minji Lee] SK Biopharm announced on the 25th that it has signed a pharmaceutical supply contract worth 66.4 billion KRW with its subsidiary SK Life Science. This amount corresponds to 16% of recent sales revenue.

The company stated, "This contract is to supply products to SK Life Science, our local subsidiary in the United States, for the sales of the new epilepsy treatment drug Cenobamate in the U.S. market," and added, "This is an internal transaction that is not recorded as sales in the consolidated financial statements."